We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

XBiotech Inc (XBIT) NPV

Sell:$11.74 Buy:$11.79 Change: $0.04 (0.34%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
Change: $0.04 (0.34%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
Change: $0.04 (0.34%)
Market closed |  Prices as at close on 2 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases. The Company is engaged in the development of biotech manufacturing technologies designed to flexibly produce therapies. It has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. It has also developed commercial scale manufacturing technology that reduces the time to launch new product candidates. It is focused on the therapies that block a potent substance naturally produced by body, known as interleukin-1 alpha (IL-1a), that mediates tissue breakdown, angiogenesis, the formation of blood clots and inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma. The Company's True Human antibody therapeutics are developed in-house using its discovery platform.

Contact details

Building 4, 8201 E Riverside Dr Ste 100
United States
+1 (512) 3862930

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$383.64 million
Shares in issue:
30.40 million
US dollar

Key personnel

  • John Simard
    Chairman of the Board, President, Chief Executive Officer, Founder
  • Sushma Shivaswamy
    Chief Scientific Officer
  • Queena Han
    Vice President - Finance and Human Resources, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.